Floatz logo

Nuvastatic

Cancer

Natureceuticals Sdn BhdPhase 2/3Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
65/ 100

Competitive context

1412 Active assets in the Cancer cohort.

View all 50

Same molecule, other indications

Nuvastatic is also rated in:

FatigueDormant
BB
Indicative ·
64 / 100
View asset →
Quality of LifeDormant
BB
Indicative ·
64 / 100
View asset →
Chemotherapy, AdjuvantDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →